Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We upgrade our recommendation on Staples Inc ( SPLS - Analyst Report ) to ‘Neutral’ from ‘Underperform’ with a target price of $12.00, following its bottom line results during the recently concluded quarter and the strategic initiatives taken by the company to boost the financial results.
Staples posted third-quarter 2012 earnings of 46 cents a share, beating the Zacks Consensus Estimate by a penny. Management expects bottom line to increase in the low-single digits for fiscal 2012.
Staples now focuses on improving store productivity by generating incremental sales per store, accelerating growth in adjacent categories, increasing market share in core office supplies, reviving international operations, and streamlining its cost structure. Through its cost-cutting endeavors, the company intends to save approximately $250 million annually by the end of fiscal 2015.
Being a leading retailer of office products and services, Staples is better positioned than its competitors, OfficeMax Inc. ( OMX - Analyst Report ) and Office Depot Inc. ( ODP - Analyst Report ) , to sustain its growth based on effective merchandising, increasing customer awareness, enhanced online features, expanded assortments and store refurbishing program. The company is gradually lowering its exposure to less profitable ventures and eyeing opportunities with lucrative growth prospects to augment profitability.
However, the quarter’s downside was the 2% decline in total sales to $6,353.1 million. Moreover, the reported revenue came well below the Zacks Consensus Estimate of $6,461.0 million. Management anticipates fiscal 2012 sales to remain at par with the prior-year level.
Alongside, gross profit for the quarter decreased 3.8% year over year to $1,751.9 million, while gross margin contracted by approximately 50 basis points from the prior-year quarter to 27.6%. Operating profit decreased by approximately 5.5% to $500 million, whereas operating margin contracted 30 basis points to 7.9%.
Going forward, we remain cautious on the macroeconomic environment and a sluggish job market, with small businesses and consumers still remaining watchful on their spending.
Currently, shares of Staples hold a Zacks #2 Rank that translates into a short-term “Buy” rating, and well defines the slew of measures undertaken by the company to uplift itself.
Read the full reports :
Analyst Report on ODP
Analyst Report on SPLS
Analyst Report on OMX